MPM BioImpact LLC filed an amended beneficial ownership statement with the SEC on November 13, 2026, disclosing a 4.8% stake in DBV Technologies S.A. as of September 30, 2026.

Key Highlights

  • Reporting person: MPM BioImpact LLC, a Delaware-organized investment adviser, filed Amendment No. 3 to its beneficial ownership statement.
  • Shares held: 15,223,295 ordinary shares of DBV Technologies S.A., held entirely through American Depositary Shares (ADSs), with each ADS representing five ordinary shares.
  • Ownership percentage: The 15,223,295 shares represent 4.8% of the class, as stated in the filing.
  • Voting and dispositive power: MPM BioImpact LLC reported sole voting power and sole dispositive power over all 15,223,295 shares, with no shared power reported.
  • Triggering date: The event requiring this filing occurred on September 30, 2026, according to the statement.
  • Certification: The filing includes a certification that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

MPM BioImpact's Position in DBV Technologies Ordinary Shares

According to the filing, MPM BioImpact LLC, based at 399 Boylston Street, Suite 1100, Boston, MA 02116, holds 15,223,295 ordinary shares of DBV Technologies S.A. (NASDAQ:DBVT), a French biopharmaceutical company headquartered at 177-181 Avenue Pierre Brossolette, Montrouge, France. The ordinary shares carry a nominal value of 0.10 euro per share. The filing identifies CUSIP number 23306J309 as assigned to the company's American Depositary Shares, noting that no separate CUSIP number has been assigned to the ordinary shares themselves.

The filing states that all 15,223,295 ordinary shares reported are represented by ADSs, with each ADS corresponding to five ordinary shares. MPM BioImpact LLC is classified in the filing as an investment adviser (type "IA"). The amendment, designated Amendment No. 3, was signed by Christopher Wolf, Chief Financial Officer of MPM BioImpact LLC, on November 13, 2026. The filing indicates that ownership has fallen to 5 percent or less of the class, satisfying the threshold noted under Item 5 of the statement.

The filing's certification attests that the securities were not acquired and are not held for the purpose of changing or influencing control of DBV Technologies S.A., and were not acquired in connection with any transaction having that effect, other than activities solely in connection with a nomination under Rule 240.14a-11, as stated verbatim in the document.

What Was Disclosed

MPM BioImpact LLC disclosed beneficial ownership of 15,223,295 ordinary shares of DBV Technologies S.A., representing 4.8% of the class as of September 30, 2026, held entirely through ADSs, with sole voting and dispositive power and no shared power reported.